These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25367997)

  • 21. Outcomes of the 340B Drug Pricing Program: A Scoping Review.
    Knox RP; Wang J; Feldman WB; Kesselheim AS; Sarpatwari A
    JAMA Health Forum; 2023 Nov; 4(11):e233716. PubMed ID: 37991784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation of a $4 generic drug program in a 340B pharmacy.
    Bright DR; Adams AJ; Akala FO; Lengel AJ; Martin SJ; Powers MF
    Am J Health Syst Pharm; 2010 Jun; 67(11):929-31. PubMed ID: 20484217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 340B Contract pharmacy growth by pharmacy ownership: 2009-2022.
    McGlave C; Bruno JP; Watts E; Nikpay S
    Health Aff Sch; 2024 Jan; 2(1):qxad075. PubMed ID: 38756399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the 340B Drug Discount Program in Recent Cancer Care Trends.
    Kantarjian HM; Chapman R
    J Oncol Pract; 2015 Jul; 11(4):303-7. PubMed ID: 26036268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of patient assistance programs and the 340B Drug Pricing Program on medication cost.
    Castellon YM; Bazargan-Hejazi S; Masatsugu M; Contreras R
    Am J Manag Care; 2014 Feb; 20(2):146-50. PubMed ID: 24738532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of medication access services at 340B and non-340B hospitals.
    Rana I; von Oehsen W; Nabulsi NA; Sharp LK; Donnelly AJ; Shah SD; Stubbings J; Durley SF
    Res Social Adm Pharm; 2021 Nov; 17(11):1887-1892. PubMed ID: 33846100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Community Health Center 340B Program: A Qualitative Study of the Experiences of Patients with Diabetes.
    Wagner AA; Whitner JB; Williams AC; Hirt KL; Miracle TL; Valentino AS
    Innov Pharm; 2023; 14(3):. PubMed ID: 38487386
    [No Abstract]   [Full Text] [Related]  

  • 28. Consequences of the 340B Drug Pricing Program.
    Desai S; McWilliams JM
    N Engl J Med; 2018 Feb; 378(6):539-548. PubMed ID: 29365282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between initiation of 340B participation and hospital safety-net engagement.
    Nikpay SS; Buntin MB; Conti RM
    Health Serv Res; 2020 Apr; 55(2):157-169. PubMed ID: 32187392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compliance among pharmacies in California with a prescription-drug discount program for Medicare beneficiaries.
    Lewis JH; Schonlau M; Muñoz JA; Asch SM; Rosen MR; Yang H; Escarce JJ
    N Engl J Med; 2002 Mar; 346(11):830-5. PubMed ID: 11893795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tips for preparing for a 340B integrity audit.
    Wood W; Jorgenson J; Kelly W
    Healthc Financ Manage; 2012 Dec; 66(12):50-2. PubMed ID: 23252228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 33. 340B program presents opportunities--and challenges.
    Keough CL; Webster SA
    Healthc Financ Manage; 2009 Nov; 63(11):42-4, 46, 48. PubMed ID: 19891397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. US Hospital Service Availability and New 340B Program Participation.
    Owsley KM; Hasnain-Wynia R; Rooks RN; Tung GJ; Mays GP; Lindrooth RC
    JAMA Health Forum; 2024 May; 5(5):e240833. PubMed ID: 38700853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurement of unused medication in Medicare Part D residents in skilled nursing facilities.
    Bazalo G; Weiss RC
    Consult Pharm; 2011 Sep; 26(9):647-56. PubMed ID: 21896471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of concentration ratios to analyze the phenomenon of "next-door" pharmacy in Taiwan.
    Ji Chen T; Chou LF; Hwang SJ
    Clin Ther; 2006 Aug; 28(8):1225-1230. PubMed ID: 16982300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Hepatitis C Treatment Program Based in a Safety-Net Hospital Patient-Centered Medical Home.
    Lasser KE; Heinz A; Battisti L; Akoumianakis A; Truong V; Tsui J; Ruiz G; Samet JH
    Ann Fam Med; 2017 May; 15(3):258-261. PubMed ID: 28483892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule; further delay of effective date.
    Health Resources and Services Administration, HHS
    Fed Regist; 2017 May; 82(96):22893-5. PubMed ID: 28574239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of the 340B Drug Pricing Program on Critical Access Hospitals: Evidence from Medicare Part B.
    Han D
    J Health Econ; 2023 May; 89():102754. PubMed ID: 37030057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.